Namur Thrombosis and Hemostasis Center

INIS

1. patients 100%
2. anticoagulants 78%
3. thrombin 53%
4. reviews 51%
5. risks 51%
6. plasma 48%
7. laboratories 42%
8. comparative evaluations 38%
9. drugs 38%
10. concentration 37%
11. assessments 35%
12. proteins 34%
13. data 33%
14. evaluation 32%
15. testing 28%
16. levels 26%
17. heparin 25%
18. blood 23%
19. diseases 22%
20. thrombosis 21%
21. doses 20%
22. control 20%
23. antibodies 20%
24. values 20%
25. performance 19%
26. inhibition 19%
27. sensitivity 19%
28. safety 18%
29. applications 18%
30. screening 17%
31. biological markers 17%
32. administration 17%
33. monitoring 17%
34. in vitro 17%
35. tyrosine 16%
36. nanoparticles 16%
37. kinases 16%
38. humans 16%
39. women 16%
40. reagents 16%
41. covid-19 15%
42. estrogens 15%
43. cancer 14%
44. neutrophils 14%
45. vaccines 14%
46. receptors 14%
47. information 14%
48. rats 13%
49. validation 13%
50. therapy 13%
51. synthesis 13%
52. in vivo 12%
53. inflammation 12%
54. standardization 12%
55. design 12%
56. detection 12%
57. molecular weight 11%
58. vitamin k 11%
59. emergencies 11%
60. myeloid leukemia 10%
61. tissues 10%
62. toxicity 10%
63. production 10%
64. coronaviruses 10%
65. hemostatics 9%
66. range 9%
67. recommendations 9%
68. management 9%
69. surgery 9%
70. mass spectrometry 9%
71. molecules 9%
72. interactions 9%
73. populations 9%
74. venoms 8%
75. thromboplastin 8%
76. symptoms 7%
77. prothrombin 7%
78. endothelium 7%
79. accuracy 7%
80. adhesion 7%
81. clinical trials 6%
82. blood coagulation 6%
83. lungs 6%
84. medicines 6%
85. dimers 6%
86. surveys 6%
87. capacity 6%
88. reduction 6%
89. investigations 6%
90. kidneys 6%
91. hormones 6%
92. peaks 6%
93. economics 6%
94. liver 5%
95. wave forms 5%
96. kinetics 5%
97. fibrinolysis 5%
98. hemolysis 5%
99. power 5%
100. substrates 5%